Skip to content
Friday, November 20, 2026
Responsive Menu
Home
Healthcare Newsdesk
The Latest UK Healthcare News brought to you by NTSI
Search
Search
Home
Care Home News
Carers
Medicine & Clinical Practice
Arthritis
Brain Conditions
Cancer
Colds and Flu
Diabetes
Diet & Exercise
Eyecare
Menopause
Mens Health
Mental Wellbeing
Psychology
Rare Medical Conditions
Smoking
Women’s Health
Physiotherapy
Private Practice
Recruitment
Wellbeing at Work
Home
Clinical News
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
Clinical News
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
July 13, 2024
Articles From The BMJ
Post navigation
Correction: central nervous system tumours and occupational ionising radiation exposure: a nested case-control study among the ORICAMs cohort of healthcare workers in France
Demographic, socioeconomic and health determinants of depressive symptoms in adults 50 years and older from Mexico: a secondary data longitudinal analysis from the Mexican Health and Aging Study